Monograph Details
|
|
Eye Disorders
> Ocular allergy/inflammation
|
|
ZYLET |
| Manufacturer |
|
Bausch & Lomb Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid + aminoglycoside. |
| Generic Name |
|
Loteprednol etabonate 0.5% + tobramycin 0.3%, oph susp; contains benzalkonium chloride. |
| Indications |
|
Ocular inflammation associated with infection or risk thereof. |
| Children |
|
Not recommended. |
| Adults |
|
Instill 1–2 drops into the conjunctival sac of affected eye(s) every 4–6 hours; may increase to every 1–2 hours in first 24–48 hours; reduce dose as symptoms improve; max 20mL for first Rx. Reevaluate if no improvement after 2 days. |
| Contraindications |
|
Ocular fungal, viral, or mycobacterial infections. |
| Precautions |
|
Corneal or scleral thinning. Glaucoma. Monitor IOP and for secondary infections and for cataracts in prolonged use (>10 days). Monitor blood levels in combined aminoglycoside therapy. Avoid abrupt cessation. Soft contact lenses (remove during therapy). Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Secondary ocular infections, injection, superficial punctate keratitis, increased IOP, ocular discomfort (eg, burning, stinging, itching, discharge) visual/lacrimation/eyelid disorder, photophobia, corneal deposits, headache. May mask or exacerbate ocular infections. May delay wound healing and increase bleb formation after cataract surgery. In prolonged use: increased IOP, optic nerve damage, cataract formation, corneal perforation. |
| How Supplied |
|
Susp—2.5mL, 5mL, 10mL |
|
|
|
|
